CBIH
Cannabis Bioscience International Holdings, Inc.0.0005
-0.0001-23.1%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.81MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Cannabis Bioscience's Q2 FY2026 revenue fell 28% y/y to $53,266 from $74,248, driven by 45% drop in clinical trials to $40,903, yet gross profit held at 80% margin. Operating loss widened to $95,877 from $59,627 on higher professional fees, with net loss at $116,966 versus $79,528, the gap due to interest expense. Cash drained to $132, operations burned $109,205 YTD, offset by $96,385 related-party financing amid $1.4M liabilities including defaulted short-term loans. EPS reconciles at $(0.000010) on 11.6B shares. Revenue hinges on three customers.
10-Q
Q1 FY2026 results
Cannabis Bioscience's Q1 FY2026 revenue plunged 86% y/y to $24,200 from $178,887, all from clinical trials, yet gross profit held at $16,057 thanks to steady $8,143 cost of revenues. Operating loss narrowed to $74,784 from $97,604 as expenses dropped 66% sans prior share-based comp; net loss ticked to $82,645, widened by $19,815 discount amortization but offset by $29,322 derivative gain—net loss exceeds operating by 10% from interest. Cash dwindled to $223, operations burned $103,712 (offset by $90,983 related-party financing), atop $1.3M debt including defaulted short-term loans at 20-33% rates and $286K SBA EIDLs at 3.75%. Two customers drove 95% revenue. Customer concentration threatens stability.
10-K
FY2025 results
Cannabis Bioscience posted FY2025 revenue of $303K, up 22% y/y from $249K, driven solely by Alpha Research clinical trials surging to $302K from $214K while education and consulting flatlined at near-zero. Gross profit climbed to $263K yet operating loss narrowed to $421K from $486K as expenses held steady, though net loss hit $549K after $136K interest drag. Q4 momentum stayed invisible sans quarterly splits. Cash scraped $13K amid $917K working capital hole; related-party loans swelled to $623K. No annual guidance issued. Customer concentration risks 91% from two clients.
10-Q
Q3 FY2025 results
Cannabis Bioscience International Holdings posted Q3 FY2025 revenue of $14,931, down 59% y/y from $36,411, while YTD revenue climbed 55% y/y to $268,066, driven by clinical trials that made up 99% of the total. Gross loss hit $4,465 in the quarter from elevated costs, yet YTD gross profit rose to $232,505 on steady expenses; operating loss narrowed to $141,344 (q/q derived) from $159,971 y/y, with net loss at $192,443 versus $209,192 prior year, the gap widened by derivative changes and interest but offset by debt forgiveness. Diluted EPS held at $(0.00002), aligning with 10.7B weighted shares. Cash dwindled to $548 amid $209,653 operating outflow, offset by $209,445 financing inflows including related-party loans; total debt stood at ~$1.2M, featuring SBA EIDL at 3.75% over 30 years and short-term notes up to 42.5%, with $584,776 related-party payables. No non-GAAP metrics disclosed in the 10-Q. Customer concentration persists, with three clients supplying 96% of YTD revenue.
8-K
Director buys 250M shares
Cannabis Bioscience International Holdings issued 250 million common shares to director John Jones on December 27, 2024, for $75,000 at $0.0003 per share, in a conflicting interest transaction approved by disinterested board members. The deal includes a repurchase covenant if shares fall below $93,750 value by December 31, 2025, terminable if average price tops $0.000375. This injects modest capital but ties the company to potential future obligations.
ACB
Aurora Cannabis Inc.
5.53+0.41
CBDL
CBD Life Sciences Inc.
0.00+0.00
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.10+0.03
CRLBF
Cresco Labs Inc.
1.75+0.45
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
CVSI
CV Sciences, Inc.
0.03+0.00
CWBHF
Charlotte's Web Holdings Inc.
0.15+0.00
IGPK
Integrated Cannabis Solutions,
0.00+0.00
JUSHF
Jushi Holdings Inc.
0.84+0.11
NXEN
Nexien BioPharma, Inc.
0.00+0.00